Participants on polypharmacy were significantly more females (P = .0115), more obese (P = .0131), had a higher duration of diabetes (P = .0088), more comorbid conditions (P < .0001), more diabetes complications (P < .0001), using more GLDs treatment (P = .0326), insulin use (P < .0001), and more chronic medicines (P < .0001) compared to those without polypharmacy (Table 1). Here, INS is linked to diabetes mellitus.